Suppliers and packagers for generic pharmaceutical drug: EPLONTERSEN SODIUM

EPLONTERSEN SODIUM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Astrazeneca Ab	WAINUA (AUTOINJECTOR)	eplontersen sodium	SOLUTION;SUBCUTANEOUS	217388	NDA	AstraZeneca Pharmaceuticals LP	0310-9400-01	1 SYRINGE, GLASS in 1 CARTON (0310-9400-01) / .8 mL in 1 SYRINGE, GLASS	2023-12-21

EPLONTERSEN SODIUM: KEY SUPPLIERS AND MANUFACTURING LANDSCAPE

Last updated: February 19, 2026

This report analyzes the key suppliers and manufacturing landscape for Eplontersen Sodium, a novel therapeutic agent. The focus is on identifying primary manufacturers of the active pharmaceutical ingredient (API) and critical intermediates, alongside contract development and manufacturing organizations (CDMOs) involved in the drug's production. Understanding this supply chain is critical for assessing manufacturing capacity, potential bottlenecks, and supply chain resilience.

WHO ARE THE PRIMARY MANUFACTURERS OF EPLONTERSEN SODIUM API AND INTERMEDIATES?

Eplontersen Sodium, an antisense oligonucleotide targeting transthyretin (TTR) mRNA, is manufactured through complex chemical synthesis. The proprietary nature of oligonucleotide synthesis means that specific details of the primary API manufacturers are often not publicly disclosed by the drug developer. However, based on industry practice and available information, key players in the oligonucleotide API manufacturing space are likely involved.

• Ionis Pharmaceuticals is the originator of Eplontersen and a leading developer of antisense technologies. While Ionis possesses internal manufacturing capabilities for its pipeline drugs, the scale required for a commercial product often necessitates partnerships. Ionis has a history of collaborating with specialized CDMOs for commercial API production of its oligonucleotide therapies [1].

• Contract Development and Manufacturing Organizations (CDMOs) specializing in oligonucleotide synthesis are the most probable primary manufacturers for Eplontersen Sodium API and critical intermediates. These organizations possess the specialized equipment, expertise in complex multi-step synthesis, stringent quality control systems, and regulatory compliance necessary for producing high-purity oligonucleotide APIs.

  • Agilent Technologies is a significant player in the oligonucleotide manufacturing space. Their expertise in oligonucleotide synthesis and supply chain management makes them a potential supplier for various stages of Eplontersen Sodium production, including intermediates or the final API [2].
  • Thermo Fisher Scientific, through its Patheon brand, offers comprehensive CDMO services, including the manufacturing of complex molecules like oligonucleotides. Their global network and extensive experience position them as a strong candidate for API or intermediate supply [3].
  • Nitto Denko Avecia Inc. is another prominent CDMO with a dedicated focus on oligonucleotide manufacturing. Their facilities are designed for large-scale production of antisense oligonucleotides and siRNAs, making them a likely partner for commercial supply [4].
  • Carbogenics also offers oligonucleotide manufacturing services, catering to early-stage development through to commercial production. Their capabilities include synthesis, purification, and analytical services crucial for oligonucleotide API production [5].

The exact allocation of manufacturing responsibilities between Ionis's internal capabilities and external CDMOs for Eplontersen Sodium is proprietary. However, it is standard practice for companies to leverage specialized CDMOs to ensure scalability, manage risk, and maintain focus on drug discovery and development.

WHAT ARE THE KEY TECHNOLOGIES AND PROCESSES INVOLVED IN EPLONTERSEN SODIUM MANUFACTURING?

The manufacturing of Eplontersen Sodium involves a sophisticated multi-step chemical synthesis process characteristic of oligonucleotide therapeutics. This process requires specialized reagents, equipment, and analytical controls.

• Solid-Phase Synthesis: This is the foundational technology for manufacturing oligonucleotides. The growing oligonucleotide chain is attached to a solid support (e.g., a silica-based resin), and subsequent nucleotide monomers are added sequentially through a series of chemical reactions. Each addition requires precise control over reaction conditions, including temperature, reagent concentration, and reaction time.

• Phosphoramidite Chemistry: This is the most common chemical approach used in solid-phase synthesis of oligonucleotides. Nucleoside phosphoramidites are the activated building blocks that are coupled to the growing oligonucleotide chain. The process involves several steps for each nucleotide addition:

  • Detritylation: Removal of the dimethoxytrityl (DMT) protecting group from the 5' end of the growing oligonucleotide chain.
  • Coupling: Reaction of the deprotected oligonucleotide with a nucleoside phosphoramidite to form a phosphite triester linkage.
  • Capping: If coupling is incomplete, the unreacted 5' hydroxyl groups are capped with an acetyl group to prevent the formation of shorter failure sequences.
  • Oxidation: The phosphite triester linkage is oxidized to a more stable phosphodiester or phosphorothioate linkage.

• Post-Synthesis Processing:

  • Cleavage from Solid Support: The completed oligonucleotide chain is cleaved from the solid support.
  • Deprotection: Protecting groups on the nucleobases and phosphate backbone are removed under specific conditions.
  • Purification: This is a critical and often complex step to remove unreacted reagents, failure sequences, and other impurities. Techniques include:
    • Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC): Widely used for purifying oligonucleotides based on their hydrophobicity.
    • Ion-Exchange Chromatography (IEC): Utilizes the charge properties of oligonucleotides for separation.
    • Size Exclusion Chromatography (SEC): Separates based on molecular size.
  • Salt Exchange/Desalting: The purified oligonucleotide is converted to its desired salt form (e.g., sodium salt for Eplontersen Sodium) and any residual salts are removed.
  • Lyophilization: The final API is typically lyophilized (freeze-dried) to produce a stable, solid powder.

• Quality Control: Rigorous analytical testing is performed at each stage of the manufacturing process and on the final API. This includes:

  • Identity testing: Confirming the correct sequence and chemical structure.
  • Purity testing: Quantifying impurities using techniques like HPLC, mass spectrometry (MS), and capillary gel electrophoresis (CGE).
  • Assay: Determining the concentration of the active oligonucleotide.
  • Counter-ion content: Verifying the correct salt form.
  • Residual solvents: Ensuring absence of harmful solvents.
  • Endotoxin testing: Crucial for injectable drugs.

The precise chemical modifications and sequence of Eplontersen Sodium are proprietary, but as an oligonucleotide, it will undergo these fundamental manufacturing steps. The scale of commercial production dictates the need for high-throughput synthesis platforms and advanced purification technologies.

WHAT IS THE CURRENT CAPACITY AND POTENTIAL FOR EXPANSION IN OLIGONUCLEOTIDE API MANUFACTURING?

The capacity for oligonucleotide API manufacturing has expanded significantly in recent years, driven by the increasing number of oligonucleotide-based therapeutics entering clinical trials and reaching commercialization. However, scaling up production for highly complex molecules like oligonucleotides presents unique challenges.

• Current Capacity: Leading CDMOs specializing in oligonucleotide manufacturing have invested in large-scale synthesis reactors, purification equipment, and downstream processing capabilities. These facilities are designed to handle multi-kilogram to ton-scale production depending on the specific drug and its dosing regimen.

  • Nitto Denko Avecia operates large-scale manufacturing facilities with multiple synthesis trains capable of producing tens to hundreds of kilograms of oligonucleotide API per batch [4].
  • Thermo Fisher Scientific (Patheon) has global CDMO sites equipped for complex API synthesis, including oligonucleotides, with varying scales of operation [3].
  • Agilent Technologies provides manufacturing services from early-stage development to commercial supply, supporting multiple oligonucleotide programs [2].

• Expansion Drivers:

  • Growing Pipeline: The substantial number of oligonucleotide therapeutics in development across various therapeutic areas (rare diseases, cardiovascular, metabolic disorders, etc.) necessitates increased API manufacturing capacity.
  • Technological Advancements: Improvements in synthesis methodologies, automation, and purification technologies are enabling higher yields, faster cycle times, and greater efficiency, indirectly increasing effective capacity.
  • Investment in Specialized Facilities: CDMOs are continuously investing in new facilities and upgrading existing ones to meet the growing demand and evolving technological requirements of oligonucleotide manufacturing.

• Challenges to Expansion:

  • Specialized Equipment: Oligonucleotide synthesis requires highly specialized and expensive equipment (e.g., automated synthesizers, large-scale chromatography systems). Lead times for procuring and installing this equipment can be lengthy.
  • Skilled Workforce: Manufacturing complex oligonucleotides requires a highly trained and experienced workforce, including chemists, engineers, and quality control specialists. Recruiting and retaining such talent can be a bottleneck.
  • Raw Material Sourcing: Securing a reliable supply of high-quality nucleoside phosphoramidites and other critical raw materials at commercial scale can be challenging. These are often custom-synthesized and require rigorous quality control.
  • Regulatory Hurdles: Expanding manufacturing capacity requires thorough validation of new equipment and processes to meet stringent regulatory requirements (e.g., FDA, EMA). This validation process can be time-consuming and resource-intensive.
  • Process Development and Optimization: Each oligonucleotide sequence requires specific optimization of synthesis and purification parameters. Scaling up these processes from laboratory to commercial scale can uncover unforeseen issues that require significant development effort.

The overall capacity for Eplontersen Sodium production will depend on the specific manufacturing partners chosen by Ionis Pharmaceuticals and the scale of their existing or planned oligonucleotide manufacturing capabilities. Given the therapeutic class, it is likely that multiple manufacturing campaigns will be required to meet global demand, suggesting a need for substantial and potentially expanding capacity.

WHO ARE THE KEY SUPPLIERS OF CRITICAL RAW MATERIALS FOR OLIGONUCLEOTIDE SYNTHESIS?

The synthesis of Eplontersen Sodium, like other oligonucleotides, relies on a specialized set of raw materials, with nucleoside phosphoramidites being the most critical. The supply chain for these materials is specialized and can be a point of vulnerability.

• Nucleoside Phosphoramidites: These are the activated building blocks of DNA and RNA. They consist of a nucleoside (adenosine, guanosine, cytidine, or uridine derivatives) with protecting groups and a phosphoramidite moiety attached to the 3' hydroxyl group. These are complex molecules that are often custom-synthesized.

  • Carbogenics is a significant supplier of nucleoside phosphoramidites and related raw materials for oligonucleotide synthesis, offering a broad catalog and custom synthesis services [5].
  • Agilent Technologies also provides a range of phosphoramidites and reagents essential for oligonucleotide synthesis [2].
  • Thermo Fisher Scientific (through its various divisions) offers a comprehensive portfolio of reagents for nucleic acid synthesis, including phosphoramidites [3].
  • Specialized Chemical Manufacturers: Several other chemical companies focus on producing highly pure nucleoside derivatives and phosphoramidites, often acting as key suppliers to the larger CDMOs or directly to drug developers for proprietary compounds. Examples include companies involved in fine chemical synthesis and custom organic chemistry.

• Solid Supports: These are inert matrices onto which the oligonucleotide chain is built during solid-phase synthesis. Common solid supports include controlled pore glass (CPG) beads, polystyrene resins, and other polymer-based materials with functionalized surfaces. Suppliers of these specialized solid supports are crucial.

  • Suppliers like Agilent Technologies and Thermo Fisher Scientific also provide various types of solid supports for oligonucleotide synthesis [2, 3].
  • Other specialized manufacturers of chromatography media and resins are also involved.

• Reagents and Solvents: The synthesis process requires a range of high-purity reagents and solvents.

  • Coupling Reagents: Such as tetrazole or 5-phenyl-1H-tetrazole, are used to activate the phosphoramidites.
  • Oxidation Reagents: Commonly iodine solutions or sulfur sources for forming phosphorothioate linkages.
  • Detritylation Reagents: Acids like trichloroacetic acid (TCA) or dichloroacetic acid (DCA).
  • Capping Reagents: Acetic anhydride, often in combination with N-methylimidazole.
  • Solvents: High-purity acetonitrile, dichloromethane, and various alcohols are used extensively. Major chemical suppliers like Merck KGaA (MilliporeSigma), Avantor (VWR), and Fisher Scientific provide these essential solvents and reagents at the required purity grades.

• Protecting Groups: Various protecting groups are used on the nucleobases and the phosphate backbone to ensure selective reactions. These are often incorporated into the nucleoside phosphoramidite building blocks themselves or added as separate reagents.

The supply chain for these specialized raw materials is a critical component of the overall Eplontersen Sodium manufacturing process. Drug developers and their CDMO partners must establish robust relationships with multiple qualified suppliers to mitigate risks associated with single-sourcing, quality deviations, or supply disruptions. The complexity and proprietary nature of some phosphoramidites mean that securing these materials at commercial scale can require long lead times and close collaboration with manufacturers.

WHAT ARE THE REGULATORY CONSIDERATIONS FOR EPLONTERSEN SODIUM MANUFACTURING?

The manufacturing of Eplontersen Sodium is subject to stringent regulatory oversight by health authorities worldwide, primarily the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Adherence to Good Manufacturing Practices (GMP) is paramount.

• Current Good Manufacturing Practices (cGMP): All manufacturing facilities involved in the production of Eplontersen Sodium API, intermediates, and the final drug product must comply with cGMP regulations. This includes requirements for:

  • Quality Management Systems: Robust systems for process control, deviation management, change control, and CAPA (Corrective and Preventive Actions).
  • Facility and Equipment Qualification and Validation: Ensuring that facilities are designed, maintained, and operated appropriately, and that equipment is suitable for its intended use and functions consistently.
  • Process Validation: Demonstrating that the manufacturing process consistently produces material meeting predefined specifications and quality attributes. For oligonucleotides, this involves validating synthesis, purification, and lyophilization steps.
  • Analytical Method Validation: Ensuring that all test methods used for raw material testing, in-process control, and final product release are accurate, precise, specific, and reliable.
  • Raw Material Control: Strict testing and qualification of all incoming raw materials, including API, excipients, and packaging components.
  • Documentation and Record-Keeping: Comprehensive and accurate documentation of all manufacturing activities, including batch records, logs, and analytical data.
  • Personnel Training: Ensuring that all personnel involved in manufacturing activities are adequately trained and qualified.

• Drug Master Files (DMFs) / Active Substance Master Files (ASMFs): API manufacturers typically file DMFs (in the US) or ASMFs (in Europe) with regulatory authorities. These confidential documents provide detailed information about the chemistry, manufacturing, and controls (CMC) of the API. The drug product applicant (Ionis Pharmaceuticals) references these filings in their marketing authorization applications.

• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines are critical for regulatory compliance. Key guidelines relevant to Eplontersen Sodium manufacturing include:

  • ICH Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
  • ICH Q11: Development and Manufacture of Drug Substances.
  • ICH Q10: Pharmaceutical Quality System.
  • ICH Q3A/B/C/D: Impurities in New Drug Substances/Products, Residual Solvents, Elemental Impurities.

• Site Inspections: Regulatory agencies conduct regular inspections of manufacturing facilities to ensure ongoing compliance with cGMP. These inspections are a critical part of the drug approval process and ongoing market surveillance.

• Specific Considerations for Oligonucleotides:

  • Sequence Integrity: Ensuring the correct oligonucleotide sequence is synthesized and that impurities related to sequence errors (e.g., deletions, additions, modifications) are controlled and within acceptable limits.
  • Purity: The complex synthesis and purification of oligonucleotides necessitate stringent controls to minimize impurities, including failure sequences, residual reagents, and degradation products.
  • Counter-ion Characterization: Precise control and characterization of the counter-ion (e.g., sodium) are essential, as it affects the physical properties and stability of the API.

Compliance with these regulatory requirements is non-negotiable. Any deviation can lead to significant delays in drug approval, manufacturing halts, or product recalls, impacting commercial viability. Ionis Pharmaceuticals and its chosen manufacturing partners must maintain a high level of regulatory diligence throughout the product lifecycle.

Key Takeaways

• Specialized CDMOs are Primary Manufacturers: The complex synthesis of Eplontersen Sodium API and intermediates is likely handled by specialized Contract Development and Manufacturing Organizations (CDMOs) with proven expertise in oligonucleotide manufacturing. Ionis Pharmaceuticals, as the originator, may also retain some internal manufacturing capabilities.
• Key CDMO Candidates: Nitto Denko Avecia, Thermo Fisher Scientific (Patheon), Agilent Technologies, and Carbogenics are prominent players in the oligonucleotide manufacturing space and are likely involved in the Eplontersen Sodium supply chain.
• Manufacturing Process: Production relies on advanced solid-phase synthesis utilizing phosphoramidite chemistry, followed by rigorous purification and analytical testing to ensure API identity, purity, and quality.
• Capacity is Expanding but Constrained: While overall oligonucleotide API manufacturing capacity is growing due to increased demand, expansion faces challenges related to specialized equipment, skilled labor, raw material sourcing, and regulatory validation.
• Critical Raw Material Suppliers: Nucleoside phosphoramidites, solid supports, and high-purity reagents are key raw materials. Companies like Carbogenics, Agilent, and Thermo Fisher Scientific are significant suppliers, alongside broader fine chemical manufacturers.
• Stringent Regulatory Oversight: Manufacturing must comply with global cGMP standards, ICH guidelines, and undergo thorough regulatory review and site inspections. Process validation, impurity control, and sequence integrity are critical focus areas.

Frequently Asked Questions

What is the primary risk associated with the Eplontersen Sodium supply chain?

The primary risk is the reliance on a limited number of specialized CDMOs and raw material suppliers for complex oligonucleotide synthesis. Disruptions at any of these critical nodes, whether due to technical failures, quality issues, geopolitical events, or capacity constraints, could impact global supply.

How does Eplontersen Sodium's manufacturing differ from small molecule drugs?

Eplontersen Sodium, as an oligonucleotide, requires a significantly more complex, multi-step chemical synthesis process than typical small molecule drugs. This involves specialized solid-phase synthesis, intricate purification steps, and higher inherent potential for related impurities (e.g., truncated sequences), demanding more specialized facilities and expertise.

Are there any publicly disclosed manufacturing partnerships for Eplontersen Sodium?

Specific manufacturing partnerships for Eplontersen Sodium are proprietary and have not been widely disclosed by Ionis Pharmaceuticals. Such agreements are typically confidential until regulatory filings or commercial launch phases.

What is the typical lead time for securing Eplontersen Sodium API from a CDMO?

The lead time for commercial-scale Eplontersen Sodium API production can range from 6 to 18 months. This includes the time required for batch scheduling, raw material procurement, synthesis, purification, quality control testing, and regulatory batch release.

What measures are in place to ensure the quality and consistency of Eplontersen Sodium across different manufacturing batches?

Quality and consistency are ensured through strict adherence to cGMP, comprehensive process validation, in-process controls at critical steps, rigorous analytical testing of raw materials and the final API, and robust quality management systems managed by both the drug developer and its manufacturing partners.

Citations

[1] Ionis Pharmaceuticals. (n.d.). Manufacturing overview. Retrieved from https://www.ionispharma.com/patients-caregivers/manufacturing/ [2] Agilent Technologies. (n.d.). Oligonucleotide manufacturing services. Retrieved from https://www.agilent.com/en/product/life-sciences-diagnostics-applied-markets/drug-discovery-development/custom-synthesis-oligonucleotides/oligonucleotide-manufacturing-services [3] Thermo Fisher Scientific. (n.d.). Contract Development and Manufacturing Organization (CDMO) services. Retrieved from https://www.thermofisher.com/us/en/home/drug-discovery/manufacturing/cdmo-services.html [4] Nitto Denko Avecia Inc. (n.d.). Oligonucleotide Manufacturing Capabilities. Retrieved from https://www.avecianc.com/capabilities/manufacturing [5] Carbogenics. (n.d.). Oligonucleotide Synthesis. Retrieved from https://www.carbosynth.com/services/oligonucleotide-synthesis/